Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

BACKGROUND: Immune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-line treatment in advanced BTC and explored the p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Chen, Xiaofeng, Wu, Xiaofeng, Wu, Hao, Gu, Yanhong, Shao, Yang, Shao, Qianwen, Zhu, Feipeng, Li, Xiao, Qian, Xiaofeng, Hu, Jun, Zhao, Fengjiao, Mao, Weidong, Sun, Jing, Wang, Jian, Han, Gaohua, Li, Changxian, Xia, Yongxiang, Seesaha, Poshita Kumari, Zhu, Dongqin, Li, Huajun, Zhang, Junling, Wang, Guoqiang, Wang, Xuehao, Li, Xiangcheng, Shu, Yongqian
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656907/
https://ncbi.nlm.nih.gov/pubmed/33172881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001240
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados